TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00241631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: 500 u

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Theophylline
Description: Theophylline placebo capcule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: Theophylline placebo capcule
Study: NCT02728544

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise and blood tests
Description: At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and blood tests
Description: At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m
Study: NCT01279629

Intervention type: DRUG
Intervention: Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).
Description: Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.

Intervention type: DRUG
Intervention: Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).
Description: Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
Study: NCT03200275

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunocatch™ Legionella Urine Antigen Test
Description: A total number of 503 urine specimens from study participants will be tested with LUAT - Immunocatch™. This test utilises the immunochromatographic (ICT) membrane assay to detect antigenuria which has revolutionized the usage of UAT to diagnose Legionella infections. The results can be obtained within minutes and the test does not require any sophisticated laboratory support. A comparison of the ICT with the Enzyme Immuno Assay (EIA) test showed comparable performance characteristics.
Study: NCT03998670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prism Glasses
Description: Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by PACT at distance or near) equally divided between the 2 lenses

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-Prism Glasses
Description: Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism
Study: NCT04217967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixazomib
Description: the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib
Study: NCT01089023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
Study: NCT01637363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: 6 x 2 hours of psychoeducation
Study: NCT01376063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: FG-4592 on days 3,5,7,9~Rosiglitazone maleate on days 1 and 9
Study: NCT04092881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
Study: NCT01459640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Intra-articular injection; 30mg/2ml; three-weekly injection regimen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem cells
Description: Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid Orthovisc (3rd injection in a three-weekly injection regimen)
Study: NCT00567671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal collagen
Description: Corneal collagen cross-linking with riboflavin/UVA light

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Sham treatment
Study: NCT02203383

Intervention type: DEVICE
Intervention: CRT Implantation
Description: Implantation of a biventricular pacemaker or defibrillator.

Intervention type: DEVICE
Intervention: CRT Implantation
Description: Implantation of a biventricular pacemaker or defibrillator.
Study: NCT03130660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Ultrasound guidance for central line

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Ultrasound guidance for central line
Study: NCT03871101

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with scalpel for placing the healing abutment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2780 nm Er,Cr:YSGG Laser
Description: Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
Study: NCT03062553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Description: MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham/MCT
Description: The Sham/MCT group will include application of random patterns of low-grade currents to the same brain region as the neuromodulation condition.~MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: tACS is a non-invasive brain stimulation technique in which a weak electrical current is applied to the head. The current passing through the brain produces small changes in the excitability of the brain regions falling within the current flow. The current occur in an alternating manner (University of California-Berkeley, 2015).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: tACS is a non-invasive brain stimulation technique in which a weak electrical current is applied to the head. The current passing through the brain produces small changes in the excitability of the brain regions falling within the current flow. The current occur in an alternating manner (University of California-Berkeley, 2015).
Study: NCT02323204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Link for Injured Kids
Description: Psychological First Aid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: So you've been in an accident
Description: Educational materials
Study: NCT01894880

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early SSC
Description: bonding straight after birth

Intervention type: PROCEDURE
Group type: OTHER
Intervention: late SSC
Description: bonding after termination of operation
Study: NCT03790436

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaquik
Description: Study dietitian will advise each participant on target volume of Betaquik (45g MCT, 225mL Betaquik). Consuming too much MCT too quickly may cause gastrointestinal discomfort such as abdominal pain or diarrhea, this is related to its assimilation to the body. Any symptoms that do occur normally resolve in the majority of patients, and with time and persistence, GI tolerance is usually established.~Therefore the study dietitian will advise on a gradual systematic introduction to minimize any adverse effects. The daily-tolerated amount will be divided into 3-4 equal portions, taken regularly throughout the day. subjects will be advised to always take Betaquik with food, as part of meals and snacks, to help promote gastrointestinal tolerance. The goal is within the first 4 weeks participants will have reached their tolerated target volume of Betaquik.
Study: NCT03158012

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Microbial Transplant
Description: Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Microbial Transplant
Description: Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
Study: NCT03754582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Intravenous infusion.
Study: NCT02240823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adipose derived stem cells
Study: NCT02116647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoanalytic therapy
Study: NCT01758224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Stimulation
Description: The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes). A magnetic coil will be placed on participant's back to stimulate the nerves related to the breathing function. Each stimulation will last two seconds and the time between each stimulation is about half a minute. The training session will begin with low intensity FMS for 20 minutes daily. The FMS stimulation intensity will gradually increase during the 6-week training period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistive Expiratory Muscle Training
Description: The REMT training will take place in the FMS lab using a standard resistive breathing device. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home. Participants will wear a nose clip when performing the breathing exercise. The exercise protocol will begin with a low resistance level for 20 minutes a day. The resistance level will gradually increase during the 6-week training period.
Study: NCT03986580

Intervention type: DEVICE
Group type: OTHER
Intervention: Annular closure device
Description: Annular closure, following limited discectomy procedure at a single LS level between L4 and S1
Study: NCT04123912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kinesio Taping - Functional Movement Power Training
Description: Subjects assigned to the Kinesio Taping - Functional Movement Power Training (KT-FMPT) group will receive FMPT concurrent with KT. The FMPT protocol was developed by the research team with reference to common physiotherapeutic exercises for children with motor disabilities.9 It comprises 5 functional movement exercises and 6 lower-limb power/resistance training exercises using weights or resistance bands.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Jogging with placebo taping
Description: Subjects assigned to the control group will receive no FMPT or KT, but participate in a jogging intervention with placebo tape applied on their calf muscles and removed after the intervention.
Study: NCT02386891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermal Environment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermal Environment
Study: NCT02763254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: baltaleucel-T
Description: Autologous EBV-specific T cells
Study: NCT06350942

Intervention type: PROCEDURE
Intervention: one trocar-assisted retroperitoneoscopic ureteroureterostomy (OTAU)
Description: A 12 mm transverse incision was made just above the iliac crest, followed by careful dissection of the fascia and muscle layer to expose the Gerota's fascia. Entry into the retroperitoneal space was achieved with a 10-mm balloon trocar, allowing for pneumoretroperitoneum establishment. Using a 10-mm laparoscope equipped with a Maryland dissector, the ureters were dissected and isolated, followed by careful exteriorization of both upper and lower pole moiety ureters with a Babcock grasper. The pathological upper pole moiety ureter was transected, preserving the normal lower pole moiety ureter and shared blood supply, and closed with a Vicryl 4/0 suture. Subsequently, an end-to-side ureteroureterostomy was performed with a 6/0 Polydioxanone running suture, with antegrade insertion of a double J stent if not previously conducted. A final retroperitoneoscopic evaluation ensured proper anastomosis alignment, and the incision was closed without drainage.
Study: NCT04018976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVACEN 100
Description: The AVACEN 100 pulls a -30mmHg vacuum around the hand from the wrist down and applies heat (108 Fahrenheit) to the palm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AVACEN 100 heat only
Description: The AVACEN 100 applies heat (108 Fahrenheit) to the palm

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AVACEN 100 sham
Description: The AVACEN 100 does not provide heat or vacuum
Study: NCT01819129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Mealtime FIAsp administered subcutaneously (s.c., under the skin). Dose individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Mealtime insulin aspart administered subcutaneously (s.c., under the skin). Dose individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.
Study: NCT01084980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: tacrolimus 0.05mg/kg bid for 12 weeks corticosteroid 0.3 - 0.5mg/kg qd
Study: NCT02779907

Intervention type: OTHER
Intervention: No Intervention
Description: No interventions planned for this observational study
Study: NCT03511508

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ChroPreg + standard care
Description: * Ongoing update of individual maternity care plan.~* Extra consultation with the specialized midwife at 20-24 weeks of pregnancy about psychological well-being during pregnancy.~* Extra consultation with the specialized midwife at 30-33 weeks of pregnancy about individual birth preparation, breastfeeding and post-partum care.~* Possibility for psychologist consultation.~* Post-partum: Telephone follow-up by the specialized midwife 1 and 2 weeks after discharge.~* Postnatal follow-up: 4-6 weeks after delivery: conversation with specialized midwife about the pregnancy and birth.
Study: NCT01790282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol plus progesterone 100 mg IM injection
Description: estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone IM of 100 mg
Description: Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone IM of 100 mg
Description: Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer
Study: NCT01545882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
Study: NCT02540330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Study: NCT04127357

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 1450 ppm fluoride toothpaste brushing x Resin sealing (FluroShield, Dentsply, Brazil).
Description: After randomization of the children, the selected molars were allocated through a randomized sequence list in 2 groups: A. Brushing with 1450 ppm fluoride toothpaste, donated by the researcher; B. Resin Sealing (FluroShield, Dentsply, Brazil).~The teeth included in the second group (group B) underwent a second randomization: B1. With absolute isolation; B2. With relative isolation. For the group with absolute isolation, topical anesthesia and local papillary infiltration were performed for subsequent staple placement. Relative isolation was performed with cotton rollers and moisture control suction. The sealant selected was the opaque fluroshield to facilitate visualization upon visual examination during reevaluations and was applied following the manufacturer's standards. The teeth were clinically and radiographically followed at 6 and 12 months and two sessions of motivation reinforcement were performed through video and brush change at 3 and 9 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1450 ppm fluoride toothpaste brushing x Resin sealing (FluroShield, Dentsply, Brazil).
Description: After randomization of the children, the selected molars were allocated through a randomized sequence list in 2 groups: A. Brushing with 1450 ppm fluoride toothpaste, donated by the researcher; B. Resin Sealing (FluroShield, Dentsply, Brazil).~The teeth included in the second group (group B) underwent a second randomization: B1. With absolute isolation; B2. With relative isolation. For the group with absolute isolation, topical anesthesia and local papillary infiltration were performed for subsequent staple placement. Relative isolation was performed with cotton rollers and moisture control suction. The sealant selected was the opaque fluroshield to facilitate visualization upon visual examination during reevaluations and was applied following the manufacturer's standards. The teeth were clinically and radiographically followed at 6 and 12 months and two sessions of motivation reinforcement were performed through video and brush change at 3 and 9 months.
Study: NCT01900106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine + raltegravir
Description: abacavir/lamivudine + raltegravir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abacavir/lamivudine + darunavir/ritonavir
Description: abacavir/lamivudine + darunavir/ritonavir
Study: NCT04083261

Intervention type: OTHER
Intervention: DNA Genotek Oragene 600
Description: Saliva-based DNA sample collection kit

Intervention type: OTHER
Intervention: DNA Genotek Oragene 600
Description: Saliva-based DNA sample collection kit

Intervention type: OTHER
Intervention: DNA Genotek Oragene 600
Description: Saliva-based DNA sample collection kit
Study: NCT04084548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine and ketamine
Description: Perioperative lidocaine and ketamine infusion (see below for dosages and timings)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Perioperative lidocaine infusion (1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Perioperative ketamine infusion (0.5 mg/kg bolus followed by an infusion of 0.3 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Perioperative placebo infusion (normal saline)
Study: NCT03625830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)
Description: SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rapid exchange PTCA -Balloon Catheter (SeQuent® Neo)
Description: SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.